Search
Revised Hang Seng HK Stock Connect Innovative Medicines Index to Exclude CXO Companies, Focusing Purely on Core Innovators
1 week ago /
Read about 0 minute
Author：小编
The innovative medicines sector has witnessed robust performance, with the Hang Seng HK Stock Connect Innovative Medicines Index surging 60% year-to-date. To sharpen its focus on the core innovative medicines industry, Hang Seng Indexes Company has announced an upcoming revision to the index compilation methodology. Notably, this revision will exclude CXO companies (encompassing CRO, CMO, and CDMO firms), thereby ensuring that the index more purely represents leading innovative medicines enterprises. The revised scheme will take effect on September 8, 2023. Industry insiders highlight that this adjustment will enhance the index's ability to accurately mirror the growth trajectory of the innovative medicines sector.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
